The Impact Of Yangxueqingnao Granula On Neuropsychological Rating Scale Of Patients With Vascular Cognitive Impairment

With the development of social economy, culture, science and technology,human life expectancy is growing and China is getting into aging society. This mayhave result in higher prevalence of cerebrovascular disease and cognitive barriers inthe elderly.Vascular factors may lead to cognitive function obstacle and the incidenceis rising year by year.Vascular cognitive impairment occupies a large proportion ofcognitive disease, which seriously influenced the health and life quality inmiddle-aged and elderly people, and it also brought a heavy burden to the socialeconomic and spirit. So, early diagnosis and drug screening exactly can help preventthe further development of vascular cognitive impairment.Objectives: This study observed the impact of Yangxueqingnao granula onneuropsychological rating scale of the patients with vascular cognitive impairment.Methods:42in-patients with vascular cognitive dysfunction were selected fromJune2010to January2012in neurological department of dalian center hospital. Thegroup met the standard conditions and were informed consent to sign the medicalrecord.1.Record the general data:neurological examination, past history, personalhistory, family history and drug therapy status. Laboratory tests include: blood RT,urine RT, biochemical record (ions, liver function, kidney function, blood fat andblood sugar), clotting function and hemorheology inspection. Imaging examinationsinclude:head CT or MRI,electrocardiogram and carotid ultrasound examination.Nervepsychological scale assessment includes: MMSE, MoCa, ADL, CDR, HAMD.2.Patiants began to take medicine from the first day of the enrollment. Methods:take Yangxueqingnao granula (tianjin TianShiLi group Co., LTD.)4g three times per day orally, the administration period is12weeks.3.Record the patients’ therapy status during the administration period bytelephone supervision (all the drugs were bought and recorded in neurologydepartment of dalian city center hospital).4.After12-week medication, patients follow-up in clinic, and record the resultsof neurologic examination, adverse events and their drug use. The laboratory testsinclude: blood RT, urine RT, biochemical conventional (ions, liver function, kidneyfunction, blood fat and blood sugar), clotting conventional and hemorheologyinspection. Imaging examinations include: electrocardiogram and carotid ultrasoundexamination. Nerve psychological scale assessment includes: MMSE, MoCa, ADL.5.Record the event after24weeks.The statistical treatment: the data of statistical were analysed by SPSS11.5statistics software, count data by frequency (percentage) or mean±standard deviation(x±s); parameter was analysed with matching t test. The probability value of p<0.05was considered significant.Results: The MMSE score of the group before administration was22.66±2.63,and22.92.±2.70after administration. There was significant differences between thedata (before and after)(p <0.05). The MoCA score of the group before and afteradministration were20.04±2.79and20.42±2.50respectively.Contrasting the data(before and after) differences were significantly (p <0.05). ADL score before andafter administration were18.98±1.74and17.90±1.79respectively. The differenceswere statistically significant (p <0.01).The differences of hemorheology before and after administration had statisticallysignificant (p <0.05).Systolic blood pressure of the group before and after administration were155.13±20.37and151.22.±17.52respectively. The differences were statisticallysignificant. But there was no statistically significant because all the patients weregiven antihypertensive drugs.There was no significant statistically difference of carotid thickening and patchesthat before and after administration (p>0.05).Clinical observation results showed that there was no impact significant on liverfunction, kidney function, routine blood, urine,blood coagulation routine and heartrate after administration. During treatment, there were2patients got anorexia on the1st day. And there was only1patient got mild pruritus on3rd day. All the symptoms disappeared in a short episode. Yangxueqingnao granula did not lead to obviousadverse reaction.Conclusion:1.Proprietary Chinese medicine Yangxueqingnao granula can improve theneuropsychological scale integral function of vascular cognitive impairment patients,and may to delay the development of cognitive dysfunction has a therapeuticaleffect.2.Yangxueqingnao granula was safe and effective to the patients with vascularcognitive dysfunction.3.The study investigated the effectiveness of Yangxueqingnao granula with asmall sample. It’s necessary to increase the sample size in order to estimate theefficacy of Yangxueqingnao granula more exactly.